NEW YORK (GenomeWeb News) –Harvard University spin-out company Auguron Biosciences has licensed its Nucleic Acid Programmable Protein Array (NAPPA) technology to Proteomika, a subsidiary of Progenika Biopharma.
Under the agreement, Proteomika may use the NAPPA technology at its facilities for in its autoimmune research and service programs, and it may exercise an option to negotiate an exclusive license to NAPPA within the field of biomarker discovery for inflammatory bowel disease and lupus.
Proteomika CEO Laureano Simon said that lupus and IBD sufferers “need better biomarkers for diagnosis, prognosis, and drug response,” and that the NAPPA technology will provide it with multiplex technology to discover antibodies that can be applied to both diseases.
Auguron was started in early 2007 as a commercialization arm for the Harvard Institute for Proteomics.
Financial terms of the agreement were not released.